154 related articles for article (PubMed ID: 17875193)
1. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline.
Davies BJ; Herbert MK; Coller JK; Somogyi AA; Milne RW; Sallustio BC
Br J Clin Pharmacol; 2008 Mar; 65(3):347-54. PubMed ID: 17875193
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
[TBL] [Abstract][Full Text] [Related]
3. CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes.
Davies BJ; Coller JK; Somogyi AA; Milne RW; Sallustio BC
Drug Metab Dispos; 2007 Jan; 35(1):128-38. PubMed ID: 17050648
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
Sallustio BC; Westley IS; Morris RG
Br J Clin Pharmacol; 2002 Aug; 54(2):107-14. PubMed ID: 12207628
[TBL] [Abstract][Full Text] [Related]
5. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status.
Barclay ML; Sawyers SM; Begg EJ; Zhang M; Roberts RL; Kennedy MA; Elliott JM
Pharmacogenetics; 2003 Oct; 13(10):627-32. PubMed ID: 14515061
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
7. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone.
Coller JK; Joergensen C; Foster DJ; James H; Gillis D; Christrup L; Somogyi AA
Int J Clin Pharmacol Ther; 2007 Jul; 45(7):410-7. PubMed ID: 17725248
[TBL] [Abstract][Full Text] [Related]
8. Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography.
Davies BJ; Herbert MK; Coller JK; Somogyi AA; Milne RW; Sallustio BC
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Nov; 843(2):302-9. PubMed ID: 16837252
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
10. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of
Haage P; Kronstrand R; Josefsson M; Calistri S; van Schaik RHN; Green H; Kugelberg FC
Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
[TBL] [Abstract][Full Text] [Related]
13. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
Davies BJ; Coller JK; James HM; Somogyi AA; Horowitz JD; Sallustio BC
Br J Clin Pharmacol; 2006 Mar; 61(3):321-5. PubMed ID: 16487226
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic hydroxylation of perhexiline in vitro.
Sørensen LB; Sørensen RN; Miners JO; Somogyi AA; Grgurinovich N; Birkett DJ
Br J Clin Pharmacol; 2003 Jun; 55(6):635-8. PubMed ID: 12814462
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics.
Vieira CP; Neves DV; Coelho EB; Lanchote VL
Drug Metab Lett; 2018; 12(1):68-70. PubMed ID: 29676238
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib.
Perez-Ruixo JJ; Zannikos P; Ozdemir V; Franc MA; Francke S; Piotrovsky V
Cancer Chemother Pharmacol; 2006 Nov; 58(5):681-91. PubMed ID: 16544144
[TBL] [Abstract][Full Text] [Related]
19. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
de Moraes NV; Lauretti GR; Coelho EB; Godoy AL; Neves DV; Lanchote VL
Fundam Clin Pharmacol; 2016 Apr; 30(2):153-61. PubMed ID: 26947771
[TBL] [Abstract][Full Text] [Related]
20. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.
Cai WM; Chen B; Cai MH; Chen Y; Zhang YD
Br J Clin Pharmacol; 1999 May; 47(5):553-6. PubMed ID: 10336580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
